CN111183146A - 高亲和力选择性结合cxcr4的缀合物及其使用方法 - Google Patents

高亲和力选择性结合cxcr4的缀合物及其使用方法 Download PDF

Info

Publication number
CN111183146A
CN111183146A CN201880049498.7A CN201880049498A CN111183146A CN 111183146 A CN111183146 A CN 111183146A CN 201880049498 A CN201880049498 A CN 201880049498A CN 111183146 A CN111183146 A CN 111183146A
Authority
CN
China
Prior art keywords
ipr
cxcr4
high affinity
binds
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880049498.7A
Other languages
English (en)
Chinese (zh)
Inventor
J·张
L·Z·严
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mainline Biosciences Inc
Original Assignee
Mainline Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mainline Biosciences Inc filed Critical Mainline Biosciences Inc
Publication of CN111183146A publication Critical patent/CN111183146A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Optics & Photonics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201880049498.7A 2017-09-05 2018-02-17 高亲和力选择性结合cxcr4的缀合物及其使用方法 Pending CN111183146A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762554354P 2017-09-05 2017-09-05
US62/554,354 2017-09-05
PCT/US2018/018530 WO2019050564A1 (en) 2017-09-05 2018-02-17 CXCR4 SELECTIVE BINDING CONJUGATE WITH HIGH AFFINITY AND METHOD OF USING THE SAME

Publications (1)

Publication Number Publication Date
CN111183146A true CN111183146A (zh) 2020-05-19

Family

ID=65635072

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880049498.7A Pending CN111183146A (zh) 2017-09-05 2018-02-17 高亲和力选择性结合cxcr4的缀合物及其使用方法

Country Status (6)

Country Link
EP (1) EP3679053A4 (enExample)
JP (1) JP2020532496A (enExample)
KR (2) KR20230145543A (enExample)
CN (1) CN111183146A (enExample)
CA (1) CA3065086A1 (enExample)
WO (1) WO2019050564A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114832113A (zh) * 2022-03-22 2022-08-02 重庆医科大学 疏水药物-马来酰亚胺衍生物及其主动载药脂质体和应用
CN117120458A (zh) * 2022-02-11 2023-11-24 C-比奥麦克斯有限公司 靶向碳酸酐酶ix的肽配体、包含其的肽结构体及它们的用途

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11123437B2 (en) 2017-09-05 2021-09-21 Mainline Biosciences, Inc. Selective CXCR4 binding peptide conjugate and methods for making and using the same
JP2021165234A (ja) * 2018-07-03 2021-10-14 富士フイルム富山化学株式会社 Ｃｘｃｒ４結合性化合物もしくはその塩またはそれらと金属との錯体
JP7541532B2 (ja) * 2019-04-18 2024-08-28 プロビンシャル・ヘルス・サービシーズ・オーソリティ 診断及び治療のための新規な放射性標識されたｃｘｃｒ４を標的とする化合物
CN115003684A (zh) * 2020-01-26 2022-09-02 主线生物科学有限公司 同位素标记的选择性cxcr4结合肽偶联物及其制备和使用方法
EP4511384A1 (en) * 2022-04-20 2025-02-26 Provincial Health Services Authority Cxcr4-targeting compounds, and methods of making and using the same
CN116023438B (zh) * 2023-02-06 2025-07-11 中国药科大学 一种cxcr4靶向多肽及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110027175A1 (en) * 2006-02-27 2011-02-03 Technische Universitat Munchen Cancer imaging and treatment
US20150050351A1 (en) * 2013-01-02 2015-02-19 Lucia Irene Gonzalez Stereoisomer peptides, their polymer conjugates, their encapsulation into nanoparticles, and uses thereof for the treatment of diseases caused by abnormal angiogenesis.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2377579A1 (en) * 2007-05-30 2011-10-19 Eli Lilly and Company Cyclic peptide CXCR4 antagonists
IT1397901B1 (it) * 2010-01-26 2013-02-04 Consiglio Nazionale Ricerche Peptidi ciclici che legano il recettore cxcr4 e relativi usi in campo medico e diagnostico.
CN102626522B (zh) * 2012-04-12 2014-09-10 韩彦江 基于趋化因子受体cxcr4多肽类拮抗剂的多肽放射性诊断与治疗药物
IN2014KN02752A (enExample) * 2012-06-06 2015-05-08 Polyphor Ag
PL3152226T3 (pl) * 2014-06-06 2019-10-31 Univ Muenchen Tech Modyfikowane cyklopentapeptydy i ich zastosowania

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110027175A1 (en) * 2006-02-27 2011-02-03 Technische Universitat Munchen Cancer imaging and treatment
US20150050351A1 (en) * 2013-01-02 2015-02-19 Lucia Irene Gonzalez Stereoisomer peptides, their polymer conjugates, their encapsulation into nanoparticles, and uses thereof for the treatment of diseases caused by abnormal angiogenesis.

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117120458A (zh) * 2022-02-11 2023-11-24 C-比奥麦克斯有限公司 靶向碳酸酐酶ix的肽配体、包含其的肽结构体及它们的用途
US12486304B2 (en) 2022-02-11 2025-12-02 C-Biomex Co., Ltd. Peptide ligand targeting carbonic anhydrase IX, peptide construct comprising same, and uses thereof
CN114832113A (zh) * 2022-03-22 2022-08-02 重庆医科大学 疏水药物-马来酰亚胺衍生物及其主动载药脂质体和应用
CN114832113B (zh) * 2022-03-22 2023-06-20 重庆医科大学 疏水药物-马来酰亚胺衍生物及其主动载药脂质体和应用

Also Published As

Publication number Publication date
JP2020532496A (ja) 2020-11-12
CA3065086A1 (en) 2019-03-14
KR20200043970A (ko) 2020-04-28
EP3679053A4 (en) 2021-10-27
WO2019050564A1 (en) 2019-03-14
KR20230145543A (ko) 2023-10-17
EP3679053A1 (en) 2020-07-15

Similar Documents

Publication Publication Date Title
CN111183146A (zh) 高亲和力选择性结合cxcr4的缀合物及其使用方法
KR100668546B1 (ko) 수용체에 결합하는 펩티드 및 화합물
KR101169846B1 (ko) 시클릭 펩티드 ｃｘｃｒ４ 길항제
CN119192401A (zh) 异串联双环肽复合物
KR20170073611A (ko) Mt1-mmp에 특이적인 바이사이클릭 펩타이드 리간드
US11883501B2 (en) Selective CXCR4 binding peptide conjugate and methods for making and using the same
CN113474046A (zh) Il-17特异性的双环肽配体
CN116801896A (zh) Bl-8040的组合物
JP2019534893A (ja) Ｃｘｃｒ４アンタゴニストおよび使用方法
CN116768978A (zh) Nectin-4靶向肽化合物及其药物偶联物
US10639379B2 (en) High affinity CXCR4 selective binding conjugate and method for using the same
WO2021150258A1 (en) Isotopically labelled selective cxcr4 binding peptide conjugate and methods for making and using the same
WO2025122615A1 (en) Enriched and stable radioligand therapy formulations and pharmaceutical compositions comprising same
TW202541853A (zh) 增濃且安定之放射配體治療調製劑及包含彼之醫藥組成物
HK1141474B (en) Cyclic peptide cxcr4 antagonists

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20200519

WD01 Invention patent application deemed withdrawn after publication